Detail akcie Cellavision online

Business Summary: CellaVision AB is a Sweden-based company active in the medical technology sector. The Company develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The Company operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, CellaVision AB revenues increased 5% to SEK759M. Net income increased 9% to SEK153.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Interest expenses - Balancing value decrease of 70% to SEK401K (expense), Int exp on Financial Lease Liabilities decrease of 11% to SEK485K (expense).